Returns
Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.
Showing returns filed by Janssen Sciences Ireland UC .
Filed returns
48
match these filters
| Period | Registrant | Policy area | Subject, as filed | Officials named | Link |
|---|---|---|---|---|---|
| May–Aug 2026 | Janssen Sciences Ireland UC | EU Affairs | Meeting with J&J Senior Leadership in Cork to discuss upcoming Irish Presidency of the EU and competitiveness (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2026 | Janssen Sciences Ireland UC | Health | Meeting to discuss health products reimbursement process reform (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2026 | Janssen Sciences Ireland UC | Health | Meetings with Government Ministers, parliamentarians, and officials with the US Chamber of Commerce delegation in February 2026 (Public policy or programme) | 7 | On lobbying.ie |
| Sep–Dec 2025 | Janssen Sciences Ireland UC | Economic Development and Industry | Engagement with the Taoiseach (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2025 | Janssen Sciences Ireland UC | Health | Engagement with Oireachtas members on patient access to new medicines (Public policy or programme) | 3 | On lobbying.ie |
| May–Aug 2025 | Janssen Sciences Ireland UC | Health | Engagement with Albert Nolan TD on biopharma policy priorities (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2025 | Janssen Sciences Ireland UC | Economic Development and Industry | Interactions with Fianna Fáil on the life sciences sector and patient access to new medicines (Public policy or programme) | 2 | On lobbying.ie |
| Sep–Dec 2024 | Janssen Sciences Ireland UC | Economic Development and Industry | Meeting with EU Commissioner-Designate Michael McGrath (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2024 | Janssen Sciences Ireland UC | Economic Development and Industry | Engagement with Commissioner-designate Michael McGrath regarding TPLF (Legislation) | 1 | On lobbying.ie |
| Sep–Dec 2024 | Janssen Sciences Ireland UC | Economic Development and Industry | Engagement with Oireachtas members to promote shared industry priorities ahead of GE 2024 (Public policy or programme) | 4 | On lobbying.ie |
| May–Aug 2024 | Janssen Sciences Ireland UC | Health | Briefing for Opposition spokesperson on life sciences industry priorities. (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2024 | Janssen Sciences Ireland UC | Health | Engagement with John Lahart TD on the Mazars process to reform the reimbursement system (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2024 | Janssen Sciences Ireland UC | Budgetary matters | Engagement with Government & Oireachtas members re new medicines funding. (Matters involving public funds) | 7 | On lobbying.ie |
| Jan–Apr 2024 | Janssen Sciences Ireland UC | Health | Conversation with Darren O'Rourke TD (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2024 | Janssen Sciences Ireland UC | Health | Engagement with Duncan Smith TD on medicines access for Irish patients (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2024 | Janssen Sciences Ireland UC | Health | Engagement with Sinn Féin at external events (Public policy or programme) | 2 | On lobbying.ie |
| Jan–Apr 2024 | Janssen Sciences Ireland UC | Health | Conversation with John Lahart TD (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2024 | Janssen Sciences Ireland UC | Health | Informal meeting with Pádraig O'Sullivan TD (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2024 | Janssen Sciences Ireland UC | Health | Engagement with Colm Burke TD on pharmaceutical sector and patient access priorities. (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2024 | Janssen Sciences Ireland UC | Economic Development and Industry | Meetings with Sinn Féin Spokespersons on life sciences industry priorities in Leinster House (Public policy or programme) | 3 | On lobbying.ie |
| Jan–Apr 2024 | Janssen Sciences Ireland UC | Budgetary matters | Representations to elected representatives in relation to the availability of funding for reimbursement of newly approved medicines. (Public policy or programme) | 5 | On lobbying.ie |
| Sep–Dec 2023 | Janssen Sciences Ireland UC | Budgetary matters | Engagement with Oireachtas members on the need for new development funding for new medicines reimbursements in 2024 (Matters involving public funds) | 24 | On lobbying.ie |
| Sep–Dec 2023 | Janssen Sciences Ireland UC | Health | Engagement with Oireachtas members on reform of the reimbursement process for newly approved medicines (Public policy or programme) | 5 | On lobbying.ie |
| Sep–Dec 2023 | Janssen Sciences Ireland UC | Economic Development and Industry | Site tour of Visioncare Limerick facility for Oireachtas members (Public policy or programme) | 2 | On lobbying.ie |
| May–Aug 2023 | Janssen Sciences Ireland UC | Health | Sharing Information and Views on medicines reimbursement reform and IPHA campaign (Public policy or programme) | 6 | On lobbying.ie |
| May–Aug 2023 | Janssen Sciences Ireland UC | Health | Sharing Information and views on medicines reimbursement reform and patient access (Public policy or programme) | 9 | On lobbying.ie |
| Jan–Apr 2023 | Janssen Sciences Ireland UC | Health | Discussion at Health Summit on proposed reforms to medicines reimbursement (Public policy or programme) | 2 | On lobbying.ie |
| Jan–Apr 2023 | Janssen Sciences Ireland UC | Health | Discussion at Health Summit on proposed reforms to medicines reimbursement (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2023 | Janssen Sciences Ireland UC | Health | Sharing Invite to discussion series on 'Ireland & the European Health Union Series: What will it mean for rare disease'' (Public policy or programme) | 15 | On lobbying.ie |
| Sep–Dec 2022 | Janssen Sciences Ireland UC | Health | Sharing Invite to discussion series on 'Ireland & the European Health Union Series: Opportunities to Improve Irish Healthcare' (Public policy or programme) | 23 | On lobbying.ie |
| May–Aug 2022 | Janssen Sciences Ireland UC | Health | J&J hosted an exhibit at the ALDE Congress in Dublin, which showcased health and life sciences innovation from across Europe, including cutting edge treatments for cancer, robotic surgery and 3D printing,… (Public policy or programme) | 11 | On lobbying.ie |
| Jan–Apr 2022 | Janssen Sciences Ireland UC | Health | Invite to webinar series on the 'Future of Value Based Healthcare in Ireland', RCSI Dublin (Public policy or programme) | 9 | On lobbying.ie |
| Jan–Apr 2022 | Janssen Sciences Ireland UC | Health | Sharing information on challenges in medicines reimbursement process in Ireland (Public policy or programme) | 3 | On lobbying.ie |
| Sep–Dec 2021 | Janssen Sciences Ireland UC | Health | Discussion on National Development Plan priorities, energy and environmental policy (Public policy or programme) | 3 | On lobbying.ie |
| Sep–Dec 2021 | Janssen Sciences Ireland UC | Health | Event at the DePuy Synthes site in Co. Cork to mark the formal launch of Johnson & Johnson entering into an eight-year corporate power purchase agreement in Ireland (Public policy or programme) | 4 | On lobbying.ie |
| Sep–Dec 2021 | Janssen Sciences Ireland UC | Health | Sharing information on European Beating Cancer Plan and impact on Ireland (Public policy or programme) | 10 | On lobbying.ie |
| May–Aug 2021 | Janssen Sciences Ireland UC | Health | Sharing copy of a new report on Cell and Gene therapies (Public policy or programme) | 8 | On lobbying.ie |
| Jan–Apr 2021 | Janssen Sciences Ireland UC | Health | Sharing progress and information on Janssen COVID19 Vaccine clinical development, supply updates and public communication (Public policy or programme) | 11 | On lobbying.ie |
| Jan–Apr 2021 | Janssen Sciences Ireland UC | Economic Development and Industry | Highlighting the importance of STEM education & apprenticeship training for pharmaceutical industry in Ireland as well as need for continued investment in local infrastructure (Public policy or programme) | 2 | On lobbying.ie |
| Sep–Dec 2020 | Janssen Sciences Ireland UC | Economic Development and Industry | Highlighting the importance of STEM education & apprenticeship training for pharmaceutical industry in Ireland as well as need for continued investment in local infrastructure (Public policy or programme) | 3 | On lobbying.ie |
| Sep–Dec 2020 | Janssen Sciences Ireland UC | Health | Sharing information on access to new medicines for Irish patients and COVID-19 vaccine update (Public policy or programme) | 2 | On lobbying.ie |
| Jan–Apr 2020 | Janssen Sciences Ireland UC | Health | Sharing update on the timeline for the development of JnJ vaccine for COVID-19 and about some of JnJ’s local efforts to assist the health service during pandemic (Public policy or programme) | 6 | On lobbying.ie |
| Jan–Apr 2020 | Janssen Sciences Ireland UC | Health | Sharing information on backlog of approved cancer medicines and consequences for treatment of patients (Public policy or programme) | 9 | On lobbying.ie |
| May–Aug 2019 | Janssen Sciences Ireland UC | Health | Invite to visit Janssen garden ‘Grounded’ at Bloom in the Park festival (Public policy or programme) | 6 | On lobbying.ie |
| May–Aug 2019 | Janssen Sciences Ireland UC | Health | Sharing information on medicines budget trends and potential for new models of value assessment (Public policy or programme) | 4 | On lobbying.ie |
| Jan–Apr 2019 | Janssen Sciences Ireland UC | Health | Outcomes based contracting for medicines (Public policy or programme) | 5 | On lobbying.ie |
| Sep–Dec 2018 | Janssen Sciences Ireland UC | Health | Outcomes based contracting for medicines (Public policy or programme) | 6 | On lobbying.ie |
| Sep–Dec 2018 | Janssen Sciences Ireland UC | Economic Development and Industry | Impact of Brexit on the Life Sciences Sector (Public policy or programme) | 4 | On lobbying.ie |
Policy areas in these returns
| Public policy area | Filed returns | Share | Relative to the largest |
|---|---|---|---|
| Health | 34 | 70.8% | |
| Economic Development and Industry | 10 | 20.8% | |
| Budgetary matters | 3 | 6.2% | |
| EU Affairs | 1 | 2.1% |